从腮腺炎到COVID-19:社区接种率低时已接种者仍易感
本文以腮腺炎疫苗的历史经验类比COVID-19疫苗接种,指出2020年12月起美欧优先人群开始接种COVID-19疫苗,全球接种率差异大,疫苗对感染的有效性约70%至90%以上、对重症更高;资源充足地区关注高风险者加强针,接种率较高地区疫情负担似较轻,但尽可能提高初级接种覆盖对有效大流行风险管理仍极重要。
要点
- 疫苗对感染有效性约70%至90%以上,对重症更高,但取决于产品和变异株。
- 接种率较高地区疫情负担似较轻,但初级接种覆盖最大化仍极重要。
- 腮腺炎历史经验表明社区接种率低时已接种者仍易感。
核心结论
- 社区接种率低时,已接种者仍易感;尽可能提高初级接种覆盖对有效大流行风险管理仍极重要。
主要发现
- 疫苗对感染的有效性范围约70%至90%以上,对重症更高,取决于产品和SARS-CoV-2变异株。
- 资源充足地区开始关注高风险者的加强针,接种率较高地区COVID-19患者和社区影响似较少。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Vaccines against coronavirus disease 2019 (COVID-19) first became available in the United States and Europe outside clinical trials in December 2020, when administration began in high-priority populations such as healthcare workers and long-term care residents. [1] Since that time, global rollout progresses with wide variation in vaccination rates by country. [2] Depending upon product and SARS-CoV-2 variant, vaccine efficacies against infection range from approximately 70 to well over 90%, higher against severe disease. Well-resourced settings are starting to focus on booster doses among high risk persons, and locations with higher vaccination rates appear to have less COVID-19 patient and community impact. Yet, in every setting, primary vaccination to as many persons as possible remains incredibly important to effective pandemic risk management. Why this is the case, why even in settings with comparatively high vaccination rates and boosting we still should make the case that more primary vaccination matters can be answered by remembering mumps, and applying those lessons to promoting vaccine access.
引用
- Gaffney KK, Jana Broadhurst M, Brett-Major DM, et al. Mumps to COVID-19: Vaccinated persons remain vulnerable when community uptake is low. Vaccine. 2022. PMID: 35183386. doi:10.1016/j.vaccine.2022.02.046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。